In the context of vaccine development, LOS sialylation has been reported to prevent complement-dependent killing by immune sera generated in response to different OM antigens such as porin and porin peptides [80–82], Ng-ACP [26], and with the 2C7 monoclonal antibody immunotherapeutic [83]. The gene discussed is NRGN; the disease is ocular melanoma.